RemeGen Co. Ltd. Class H (HK:9995)
:9995
Want to see HK:9995 full AI Analyst Report?
9995 Stock Chart & Stats
HK$119.90
-HK$0.38(-3.04%)
At close: 4:00 PM EST
HK$119.90
-HK$0.38(-3.04%)
Day’s Range― - ―
52-Week RangeHK$43.85 - HK$126.60
Previous CloseN/A
Volume1.38M
Average Volume (3M)6.34M
Market Cap
HK$63.37B
Enterprise ValueHK$65.53B
Total Cash (Recent Filing)HK$2.74B
Total Debt (Recent Filing)HK$2.09B
Price to Earnings (P/E)36.3
Beta1.52
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.29
Shares Outstanding208,581,240
10 Day Avg. Volume6,644,676
30 Day Avg. Volume6,343,592
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)9.84
Price to Sales (P/S)11.22
P/FCF Ratio-253.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$133.24Price Target Upside11.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)6.29
Revenue Forecast (FY)HK$7.26B
Bulls Say, Bears Say
Bulls Say
Revenue Acceleration & Return To ProfitabilitySustained acceleration in revenue alongside a shift to TTM profitability signals the business has moved from development-stage losses toward commercial traction. That structural improvement supports reinvestment in R&D, strengthens partner negotiations, and increases predictability of future operating performance.
High Operating And Net MarginsRobust EBIT and net margins indicate the company can generate substantial profitability from sales, which is durable if driven by proprietary biologics and scalable manufacturing. High margins support funding of pipeline programs and create a buffer versus industry pricing pressure, enhancing long-term cash generation potential.
Improved Balance Sheet And ROEReduction in leverage versus the prior year and materially stronger return on equity reflect improving capital efficiency and a healthier funding profile. A stronger balance sheet increases strategic optionality for partnerships, licensing, or selective M&A without excessive dilution or refinancing risk.
Bears Say
Weak Cash ConversionReported earnings are not translating into cash: a very low operating cash flow to net income ratio (~0.02) raises questions about earnings quality and the durability of profits. Long-term value depends on converting accounting profits into free cash to fund operations and pipeline investment.
Volatile Free Cash Flow HistoryWide swings in free cash flow, including multi-year deep negative FCF followed by only modestly positive TTM, imply unpredictable internal funding for development and commercialization. This volatility increases reliance on external financing and raises execution risk across the pipeline lifecycle.
Historical Earnings And Capital VolatilitySubstantial historical swings from large losses to current profits and shifting leverage indicate operating and execution variability. Persistent volatility undermines forecasting, may deter long-term partners or conservative investors, and elevates the risk that current profitability may not be sustained.
RemeGen Co. Ltd. Class H News
9995 FAQ
What was RemeGen Co. Ltd. Class H’s price range in the past 12 months?
RemeGen Co. Ltd. Class H lowest stock price was HK$43.85 and its highest was HK$126.60 in the past 12 months.
What is RemeGen Co. Ltd. Class H’s market cap?
RemeGen Co. Ltd. Class H’s market cap is HK$63.37B.
When is RemeGen Co. Ltd. Class H’s upcoming earnings report date?
RemeGen Co. Ltd. Class H’s upcoming earnings report date is Aug 26, 2026 which is in 97 days.
How were RemeGen Co. Ltd. Class H’s earnings last quarter?
RemeGen Co. Ltd. Class H released its earnings results on Apr 28, 2026. The company reported HK$0.665 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.665.
Is RemeGen Co. Ltd. Class H overvalued?
According to Wall Street analysts RemeGen Co. Ltd. Class H’s price is currently Undervalued.
Does RemeGen Co. Ltd. Class H pay dividends?
RemeGen Co. Ltd. Class H does not currently pay dividends.
What is RemeGen Co. Ltd. Class H’s EPS estimate?
RemeGen Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RemeGen Co. Ltd. Class H have?
RemeGen Co. Ltd. Class H has 208,581,240 shares outstanding.
What happened to RemeGen Co. Ltd. Class H’s price movement after its last earnings report?
RemeGen Co. Ltd. Class H reported an EPS of HK$0.665 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.476%.
Which hedge fund is a major shareholder of RemeGen Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:9995
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RemeGen Co. Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$133.24 (11.12% Upside)
HK$133.24 (11.12% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
495.23%
12-Months-Change
Fundamentals
Return on Equity
32.32%
Trailing 12-Months
Asset Growth
37.96%
Trailing 12-Months
Company Description
RemeGen Co. Ltd. Class H
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors, as well as lung and urothelial cancer; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company's products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC208, RC218, and RC228 to treat ophthalmic diseases. RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.
9995 Stock 12 Month Forecast
Average Price Target
HK$133.24
▲(11.12% Upside)
Technical Analysis
Akeso, Inc.
―
Alphamab Oncology
―
InnoCare Pharma Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Options Prices
Currently, No data available
---